Previous 10 | Next 10 |
85,000 square foot state-of-the-art facility being built in Rockville, Maryland Accelerates TCR 2 ’s commercial-scale manufacturing timelines with production anticipated in 2023 Aaron Vernon hired as Vice President of Technical Operations CAMBRIDGE, Mass., March...
TCR2 Therapeutics (TCRR): Q4 GAAP EPS of -$0.55 beats by $0.02.Cash, cash equivalents, and investments of $228.0 million at the end of 2020 compared to $158.1 million as of December 31, 2019.Press Release For further details see: TCR2 Therapeutics EPS beats by $0.02
- Preliminary safety, efficacy and translational data from gavo-cel Phase 1 trial at AACR 2021 - Preclinical data on autologous CD70 and allogeneic mesothelin TRuC data at AACR 2021 - Raised gross proceeds of $140M in a follow-on offering in Januar...
CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that three e-poster presentations featuring new clinical data...
CAMBRIDGE, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that management will present an update on Company progress at...
CAMBRIDGE, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that Ian Somaiya, Chief Financial Officer of TCR 2 Therape...
CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR) (“TCR 2 ” or the “Company”), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced th...
TCR2 Therapeutics (TCRR) has priced its public offering of ~4.6M common shares at $30.50/share, for expected gross proceeds of ~$140M.Underwriters' over-allotment is an additional ~688.5K shares. Net proceeds will be used to advance its clinical programs, for R&D activities, working capit...
CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR) (“TCR 2 ” or the “Company”), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced th...
TCR2 Therapeutics ([[TCRR]] -0.4%) commences an underwritten public offering of $125M of shares of common stock.Underwriter's option to purchase up to an additional $18.75M shares.Actual size and terms yet to be finalised.Company intends to use the net proceeds to advance its ...
News, Short Squeeze, Breakout and More Instantly...
TCR2 Therapeutics Inc. Company Name:
TCRR Stock Symbol:
NASDAQ Market:
TCR2 Therapeutics Inc. Website:
CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR) (TCR 2 or the Company), a clinical-stage cell therapy company with a pipeline of novel next-generation T cell therapies for patients suffering from solid tumors, today announced financial results for...
NEW YORK, NY / ACCESSWIRE / April 2, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Radius Global Infrastructure, Inc....
NEW YORK, NY / ACCESSWIRE / March 30, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: U.S. Xpress Enterprises, Inc. (NYSE:...